Search
01/06/2022
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Arriola, E, Gonzalez-Cao, M, Domine, M, De Castro, J, Cobo, M, Bernabe, R, Navarro, A, Sullivan, I, Trigo, JM, Mosquera, J, Crama, L, Isla, D. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncology And Therapy. 2022; 10(1)DOI:10.1007/s40487-021-00182-0. PMID:35032007. IF:(Q/D).
01/06/2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Majem, M, Goldman, JW, John, T, Grohe, C, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Li, SQ, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Atagi, S, Zeng, LM, Kulkarni, D, Medic, N, Tsuboi, M, Herbst, RS, Wu, YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. CLINICAL CANCER RESEARCH. 2022; 28(11)DOI:10.1158/1078-0432.CCR-21-3530. PMID:35012927. IF:11.500(Q1/1D).
01/06/2022
SELNET clinical practice guidelines for bone sarcoma
Blay, JY, Palmerini, E, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara-Altamirano, MA, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, Tos, APD, Malagon, HRD, Donati, DM, Dufresne, A, Eriksson, M, Farias-Loza, M, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gerderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Hindi, N, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes, A, David, BBL, Lopez-Pousa, A, Lutter, G, Maki, RG, Martinez-Said, H, Martinez-Tlahuel, JL, Mello, CA, Perez, JMM, Moura, DS, Nakagawa, SA, Nascimento, AG, Ortiz-Cruz, EJ, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Santos, TG, Scotlandi, K, Silva, MLG, Soule, T, Stacchiotti, S, Valverde, CM, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for bone sarcoma. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103685. PMID:35460913. IF:6.200(Q1/3D).
01/06/2022
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
Lindskog, M, Laurell, A, Kjellman, A, Melichar, B, Rey, PM, Zielinski, H, Villacampa, F, Bigot, P, Zoltan, B, Parikh, O, Alba, DV, Jellvert, D, Flasko, T, Gallardo, E, Caparros, MJR, Purkalne, G, Suenaert, P, Karlsson-Parra, A, Ljungberg, B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 2022; 40DOI:10.1016/j.euros.2022.03.012. PMID:35638086. IF:2.500(Q3/6D).
01/06/2022
The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles
Volta-Duran, E, Sanchez, JM, Hector-Lopez-Laguna, Parlade, E, Sanchez-Garcia, L, Sanchez-Chardi, A, de Marco, A, Unzueta, U, Vazquez, E, Villaverde, A. The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China-Materials. 2022; 65(6)DOI:10.1007/s40843-021-1914-0. PMID:. IF:8.100(Q1/3D).
01/06/2022
Sarcoidosis following SARS-CoV-2 infection: Cause or consequence?
Palones, E, Pajares, V, Lopez, L, Castillo, D, Torrego, A. Sarcoidosis following SARS-CoV-2 infection: Cause or consequence?. Respirology Case Reports. 2022; 10(6)DOI:10.1002/rcr2.955. PMID:35505665. IF:(Q/D).